Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03947320
Other study ID # SCT800-A303
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date December 20, 2019
Est. completion date September 20, 2020

Study information

Verified date May 2019
Source Sinocelltech Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a multicenter phase III uncontrolled open-label trial to evaluate the efficacy,safety and pharmacokinetics of SCT800 in regular prophylaxis and perioperative treatment in patients (<12 years old) with severe hemophilia A who have been previously treated with coagulation factor VIII(FVIII) . This study includes two phases: the screening period and prophylaxis period.Prophylaxis with 25 - 50 IU/kg of SCT800 shall be administered once every other day or three times per week starting from Visit 1 and prophylaxis with SCT800 shall continue for 24 consecutive weeks.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 70
Est. completion date September 20, 2020
Est. primary completion date September 20, 2020
Accepts healthy volunteers No
Gender Male
Age group N/A to 12 Years
Eligibility Inclusion Criteria:

- Aged <12 years ;

- Male severe (central laboratory tested FVIII:C <1%) hemophilia A patients;

- Previously received FVIII treatment (prophylactic or bleeding treatment), have the relevant records and are verified to have accumulated EDs =150 days(6=age<12years old)and EDs >50 days(age <6 years old);

- The bleeding treatment records of at least 3 months before screening can be obtained;

- Negative FVIII inhibitor assay results (laboratory tested Nijmegen-Bethesda assay result <0.6 BU/mL);

- HIV negative; if HIV positive, the viral load <200 particles/uL or <400,000 copies/mL, and HIV patients must satisfy CD4+ count >200/µL;

- The patient or his guardian voluntarily signed the Informed Consent Form.

Exclusion Criteria:

- Known allergy to any coagulation factor VIII or any excipient; known allergy to bovine, rodent or hamster bovine;

- Has a history or family history of blood coagulation factor VIII inhibitor;

- Platelet count <100 × 109/L;

- Clinical liver function test ((glutamic-pyruvic transaminase, glutamic-pyruvic transaminase) = five times the upper limit of normal (ULN) or clinical kidney function test (creatinine) = two times the ULN;

- International normalized ratio (INR) >1.5;

- Patients with other coagulation dysfunction diseases in addition to hemophilia A;

- Patients who used any anticoagulant or anti-platelet treatment (including non-steroidal anti-inflammatory drugs [NSAIDs]) within 1 weeks before the first drug administration or who regularly (e.g., daily, every other day) use anticoagulant or anti-platelet treatment within the clinical trial period;

- Patients who used immunomodulator(e.g., immunoglobulin, corticosteroids,alpha-interferon, prednisone [>10 mg/day and >7 days], or comparable drugs, other than anti-retroviral chemotherapy) within two weeks before the first administration of the study drug or during the clinical trial period;

- Administration of any cryoprecipitate, whole blood or plasma within 30 days prior to administration of study drug.

- Patients with other clinically significant diseases, alcoholism, drug abuse, mental disorders or intellectual disabilities;

- Patients with other severe or clinical significant diseases verified by the investigator to be unable to benefit from the clinical study;

- Patients who participated in other clinical studies within one month before the first drug administration (except FVIII trials) and patients who participated in other FVIII clinical trials after signing the Informed Consent Form;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Recombinant Human Coagulation FVIII
Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sinocelltech Ltd.

Outcome

Type Measure Description Time frame Safety issue
Other Incidence of FVIII inhibitors The Nijmegen-Bethesda assay shall be used to monitor the production of FVIII inhibitors during the trial. up tp 24 weeks
Primary Annualized Bleeding Rate Annualized Bleeding Rate(ABR) can be calculated using the following formula: Number of bleeding events in efficacy evaluation period/(number of days in treatment period/365.25) up to 24 weeks
Secondary Annualized joint bleeding rate Annualized joint bleeding rate(AJBR) can be calculated using the following formula: Number of joint bleeding events during efficacy evaluation period/(number of days in treatment period/365.25). up to 24 weeks
Secondary FVIII incremental in-vivo recovery Incremental recovery is determined as the peak factor level recorded in the first hour after infusion and is reported as [IU/ml]/[IU/kg] Predose within 30 min,15 min±2 min
Secondary Bleeding event treatment efficacy The investigator shall evaluate the hemostatic effect after the treatment of every bleeding event of subjects based on a four-point scale(excellent, good, moderate, not relieved). up to 24 weeks
Secondary Elimination Half Life t1/2; Chromogenic Assay Predose within 30 min,15 min±2 min?1 hour±5 min,10 hours±30 min,24 hours±1hours and 48 hours±2 hours post-dose
Secondary Clearance CL; Chromogenic Assay Predose within 30 min,15 min±2 min?1 hour±5 min,10 hours±30 min,24 hours±1hours and 48 hours±2 hours post-dose
See also
  Status Clinical Trial Phase
Completed NCT03834727 - Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
Completed NCT03191799 - A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors Phase 3
Completed NCT01599819 - BAX 855 Dose-Escalation Safety Study Phase 1
Terminated NCT04541628 - Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A Phase 1/Phase 2
Completed NCT02847637 - A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors Phase 3
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Completed NCT04085458 - Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation) Phase 4
Completed NCT04565236 - A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A Phase 4
Recruiting NCT05987449 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A Phase 1/Phase 2
Active, not recruiting NCT04621916 - Preventing Inhibitor Recurrence Indefinitely Phase 4
Not yet recruiting NCT02888223 - Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A Phase 1
Completed NCT02528968 - National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A N/A
Completed NCT02225483 - Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function N/A
Completed NCT02199717 - An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia N/A
Completed NCT01217255 - Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
Terminated NCT00995046 - Individually Tailored Prophylaxis in Patients With Severe Hemophilia A N/A
Completed NCT00969319 - Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America N/A
Completed NCT00868530 - Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects Phase 3
Completed NCT00839202 - Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay N/A
Completed NCT00629837 - Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 Phase 1